P ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNOTE-756 & BEGONIA" By Insights from 2023 ESMO Annual Meeting FEATURING Paolo Tarantino November 3, 2023 Comments 2 Login to view comments. Click here to Login Featured Video 03:15 Lilly Medical Affairs Unmet Needs...
Breast cancer is the most prevalent kind of cancer among women and there is a need for a reliable algorithm to predict its prognosis. Previous studies focused on using gene expression data to build predictive models. However, recent advancements have made multi-omics cancer data sets (gene expres...
At ASCO 2024, Avan J. Armaghani, MD, highlights two key presentations. First, a retrospective study on adjuvant endocrine therapy in ER-low breast cancer (1%-10% ER-positivity) demonstrated that patients who skipped this therapy had significantly worse overall survival, especially those who receiv...
标题:Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials 报告人:陈海珠(中国,广州) 时间:16:40 - 16:45 04 摘要号:240MO 标题:Prognostic and predictive impact of e...
We aim to develop a nomogram incorporating radiomics and the Breast Imaging Reporting and Data System (BI-RADS) for predicting breast cancer in BI-RADS ultrasound (US) category 4 or 5 lesions. From January 2017 to August 2018, a total of 315 pathologically proven breast lesions were included....
Fig. 1. Dominant topics in early breast cancer research in 2023 Abbreviations: HR: hormone receptor, TNBC: triple negative breast cancer. Created with BioRender.com. 2. Breast cancer treatment 2.1. Local therapy Routine use of sentinel lymph node biopsy (SLN) has allowed many patients to safely...
Dec 1, 2023 Virginia Kaklamani, MD, GuestRobert A. Figlin, MD, FACP, HostStudies involving high-risk, early-stage, ER-positive breast cancer are among the most eagerly anticipated at this year’s San Antonio Breast Cancer Symposium (SABCS), to be held Dec. 5-9. Virginia ...
Ryvu Therapeutics today announced promising translational data on RVU120 in combination with MEK inhibitors at the San Antonio Breast Cancer Symposium (SABCS) 2023.
Breast Cancer Diagnostics Global Market Report 2023. Including: 1) By Type: Imaging; Biopsy; Genomic Tests; Blood Tests2) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC)3) By Can
The symposium also had the objectives of increasing communication and collaboration among breast cancer healthcare providers nationwide and providing a comprehensive and real-life review of the many facets of breast cancer. The sessions covered the patient voice, the top breast cancer ...